Elon Musk has confirmed that X’s long-promised payments layer, X Money, is already running inside the company — but Dogecoin, his on-again-off-again favorite memeElon Musk has confirmed that X’s long-promised payments layer, X Money, is already running inside the company — but Dogecoin, his on-again-off-again favorite meme

Dogecoin Barely Blinks As Musk Confirms X Money Is Running Internally

2025/12/12 08:00
3 min read

Elon Musk has confirmed that X’s long-promised payments layer, X Money, is already running inside the company — but Dogecoin, his on-again-off-again favorite meme coin, has barely twitched.

Replying to developer and X feature-watcher Nima Owji on December 10, Musk dropped a characteristically terse update: “It has been launched internally.” Within hours, promoter Mario Nawfal was broadcasting that “X MONEY IS LIVE BEHIND CLOSED DOORS, PUBLIC LAUNCH NEXT,” describing the system as “quietly tested by employees and early users while the rest of the world waits for access.”

The market, however, did not exactly wait breathlessly. As of press time, Dogecoin traded around $0.137, down less than 0.1% on the day — essentially noise, given an intraday range between roughly $0.137 and $0.150. For a coin that once ripped 20–30% on a single Elon meme, this is… subdued.

Why Is The Dogecoin Price Not Reacting?

The contrast with earlier X Money headlines is stark. When Musk first framed the payments stack as part of a broader relaunch of XChat in mid-November, he boasted that X had “just rolled out an entire new communications stack with encrypted messages, audio/video calls and file transfer,” adding pointedly: “Money comes out soon… X will be the everything app.”

Dogecoin and other high-beta names squeezed higher on that story, if only briefly. Back in May, when Musk confirmed that a beta version of X Money was coming, DOGE jumped from about $0.08 to $0.09 on the announcement — a double-digit percentage move triggered by one more hint that the dog might be wired into X’s rails.

Today’s non-reaction lands against a deeper build-out of X Money in the background. According to a recent job posting, X Money is hiring a technical lead to design a payments platform “from the ground up” for more than 600 million monthly users, with an emphasis on distributed systems and secure transactions.

The description notably does not mention crypto or Dogecoin at all. Notably, X Money already announced a partnership with Visa earlier this year for an “X Money Account” that would fund wallets and peer-to-peer payments, while Solana figures — including ecosystem advisor Nikita Bier, now at X — have publicly signaled they are eager to help.

Crucially, Musk has not exactly gone quiet on Dogecoin in general. On November 3 he posted “It’s time” on X, reviving his old promise to “put a literal Dogecoin on the literal moon” via a SpaceX mission, as reported by Bitcoinist.

In mid-October he waded into the “energy money” debate, backing Bitcoin as impossible to “fake” because it is grounded in energy and then replying with an approving emoji when a Dogecoin community account insisted that “Dogecoin is also based on energy” — his “first explicit nod toward DOGE in a while,” as reported on NewsBTC.

Even more recently, on October 11 and again on November 15, Musk posted Doge-coded content — a Shiba Inu mascot image, then a meme of a Shiba playing a banjo — that historically would have lit up DOGE order books. However, this time, Dogecoin’s response was muted to outright negative.

In other words, the last few times Musk has talked about or referenced Dogecoin on X, the market reaction has been steadily decaying. So when he now says X Money “has been launched internally,” the absence of a pump in DOGE looks less like a mystery and more like a trend.

At press time, DOGE traded at $0.13765.

Dogecoin price chart
Market Opportunity
Dogelon Mars Logo
Dogelon Mars Price(ELON)
$0.00000003282
$0.00000003282$0.00000003282
-1.50%
USD
Dogelon Mars (ELON) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26